The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer’s Disease and Beyond
نویسندگان
چکیده
The β-site APP cleaving enzyme 1 (BACE1) is a transmembrane aspartyl protease involved in Alzheimer's disease (AD) pathogenesis and in myelination. BACE1 initiates the generation of the pathogenic amyloid β-peptide, which makes BACE1 a major drug target for AD. BACE1 also cleaves and activates neuregulin 1, thereby contributing to postnatal myelination, in particular in the peripheral nervous system. Additional proteins are also cleaved by BACE1, but less is known about the physiological consequences of their cleavage. Recently, new phenotypes were described in BACE1-deficient mice. Although it remains unclear through which BACE1 substrates they are mediated, the phenotypes suggest a versatile role of this protease for diverse physiological processes. This review summarizes the enzymatic and cellular properties of BACE1 as well as its regulation by lipids, by transcriptional, and by translational mechanisms. The main focus will be on the recent progress in understanding BACE1 function and its implication for potential mechanism-based side effects upon therapeutic inhibition.
منابع مشابه
Application of a Bioinformatics-Based Approach to Identify Novel Putative in vivo BACE1 Substrates
BACE1, a membrane-bound aspartyl protease that is implicated in Alzheimer's disease, is the first protease to cut the amyloid precursor protein resulting in the generation of amyloid-β and its aggregation to form senile plaques, a hallmark feature of the disease. Few other native BACE1 substrates have been identified despite its relatively loose substrate specificity. We report a bioinformatics...
متن کاملExpression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer\'s disease
Background: Recent evidence has indicated that beta-secretase 1 (BACE1) is involved in the production of amyloid beta (Aβ) in patients affected with Alzheimer’s disease (AD). Therefore; the purpose of this study was to measure mRNA and plasma levels of BACE1 in AD patients, as an early diagnosis biomarker for such individuals. Methods: A total number of thirty AD patients and thirty normal sub...
متن کاملA Peptide Binding to the β-Site of APP Improves Spatial Memory and Attenuates Aβ Burden in Alzheimer’s Disease Transgenic Mice
Amyloid precursor protein cleaving enzyme 1 (BACE1), an aspartyl protease, initiates processing of the amyloid precursor protein (APP) into β-amyloid (Aβ); the peptide likely contributes to development of Alzheimer's disease (AD). BACE1 is an attractive therapeutic target for AD treatment, but it exhibits other physiological activities and has many other substrates besides APP. Thus, inhibition...
متن کاملBiophysical properties of single potassium channel in the brain mitochondrial inner membrane of male rat with Alzheimer’s disease
Introduction: Alzheimer’s disease is a progressive neurodegenerative disorder, characterized by impairment of memory and changes in behavior and personality. Recent evidence suggests that mitochondrial channels play important roles in memory disorders. Accordingly, the biophysical properties of a single potassium channel were investigated in the brain mitochondrial inner membrane of rat with...
متن کاملThe Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer’s Disease
Alzheimer’s disease (AD) is a very serious public health problem. Currently, there is no effective treatment for AD. Among the many biochemical targets for AD drug development, β-secretase (BACE1, memapsin 2) continues to be a promising drug discovery target for AD therapy. This proteolytic enzyme is a membrane-anchored aspartic acid protease that is responsible for the initial step of amyloid ...
متن کامل